Re­gen­eron ex­pects key Dupix­ent COPD da­ta this year amid Eylea's sales de­cline in the US

One of the drug in­dus­try’s best-sell­ing ther­a­pies could be clos­er than ex­pect­ed to be­com­ing the first bi­o­log­ic to treat COPD, or chron­ic ob­struc­tive pul­monary dis­ease.

In an­nounc­ing third-quar­ter re­sults on Thurs­day, Re­gen­eron said an in­ter­im analy­sis of a Phase III COPD study could sup­port fil­ing Dupix­ent for ap­proval with the FDA. The New York biotech said the da­ta mon­i­tor­ing com­mit­tee plans to take a look at the in­ter­im da­ta lat­er this year and re­cent feed­back from the FDA sup­port­ed this plan.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER